Bicycle Therapeutics Plc - ADR

+0.54 (+2.14%)
Earnings Announcements

Bicycle Therapeutics Says Qtrly Net Loss Was $26.8 Million

Published: 08/04/2022 12:01 GMT
Bicycle Therapeutics Plc - ADR (BCYC) - Cash and Cash Equivalents of $372.8 Million As of June 30, 2022.
Expected Financial Runway Into 2025.
Net Loss Was $26.8 Million, Or $0.90 Basic and Diluted Net Loss per Share, for Three Months Ended June 30, 2022.
Q2 Earnings per Share View $-0.85 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $6.61 Million
Adjusted EPS is expected to be -$0.85

Next Quarter Revenue Guidance is expected to be $4.9 Million
Next Quarter EPS Guidance is expected to be -$1.00

More details on our Analysts Page.